1. Home
  2. INSM vs WSM Comparison

INSM vs WSM Comparison

Compare INSM & WSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INSM
  • WSM
  • Stock Information
  • Founded
  • INSM 1988
  • WSM 1956
  • Country
  • INSM United States
  • WSM United States
  • Employees
  • INSM N/A
  • WSM 19600
  • Industry
  • INSM Biotechnology: Pharmaceutical Preparations
  • WSM Home Furnishings
  • Sector
  • INSM Health Care
  • WSM Consumer Discretionary
  • Exchange
  • INSM Nasdaq
  • WSM Nasdaq
  • Market Cap
  • INSM 26.0B
  • WSM 24.7B
  • IPO Year
  • INSM 2000
  • WSM N/A
  • Fundamental
  • Price
  • INSM $145.10
  • WSM $202.25
  • Analyst Decision
  • INSM Strong Buy
  • WSM Buy
  • Analyst Count
  • INSM 19
  • WSM 16
  • Target Price
  • INSM $142.38
  • WSM $199.13
  • AVG Volume (30 Days)
  • INSM 3.0M
  • WSM 1.5M
  • Earning Date
  • INSM 10-30-2025
  • WSM 08-27-2025
  • Dividend Yield
  • INSM N/A
  • WSM 1.30%
  • EPS Growth
  • INSM N/A
  • WSM 9.54
  • EPS
  • INSM N/A
  • WSM 9.01
  • Revenue
  • INSM $398,105,000.00
  • WSM $7,829,759,000.00
  • Revenue This Year
  • INSM $32.47
  • WSM $1.50
  • Revenue Next Year
  • INSM $126.03
  • WSM $3.00
  • P/E Ratio
  • INSM N/A
  • WSM $22.46
  • Revenue Growth
  • INSM 21.15
  • WSM 3.28
  • 52 Week Low
  • INSM $60.40
  • WSM $125.33
  • 52 Week High
  • INSM $146.84
  • WSM $219.98
  • Technical
  • Relative Strength Index (RSI)
  • INSM 79.86
  • WSM 59.13
  • Support Level
  • INSM $128.02
  • WSM $186.00
  • Resistance Level
  • INSM $146.84
  • WSM $205.00
  • Average True Range (ATR)
  • INSM 3.66
  • WSM 6.22
  • MACD
  • INSM 0.71
  • WSM -0.85
  • Stochastic Oscillator
  • INSM 91.65
  • WSM 79.66

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

About WSM Williams-Sonoma Inc. (DE)

With a retail and direct-to-consumer presence, Williams-Sonoma is a player in the $300 billion domestic home category and $450 billion international home market, focused on expanding its exposure in the B2B ($80 billion total addressable market), marketplace, and franchise areas. Namesake Williams-Sonoma (154 stores) offers high-end cooking essentials, while Pottery Barn (181) provides casual home accessories. West Elm (119) is an emerging concept for young professionals, and Rejuvenation (11) offers lighting and house parts. Brand extensions include Pottery Barn Kids and Pottery Barn Teen (44) as well as Mark & Graham and GreenRow. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.

Share on Social Networks: